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Abstract
Background: Pneumococcal adherence to the nasopharyngeal epithelium is a critical step in colonisation and
disease. The probiotic bacterium, Streptococcus salivarius, can inhibit pneumococcal adherence to epithelial cells in
vitro. We investigated the mechanism(s) of inhibition using a human pharyngeal epithelial cell line (Detroit 562)
following pre-administration of two different strains of S. salivarius.
Results: Whilst the bacteriocin-encoding megaplasmids of S. salivarius strains K12 and M18 were essential to
prevent pneumococcal growth on solid media, they were not required to inhibit pneumococcal adherence.
Experiments testing S. salivarius K12 and two pneumococcal isolates (serotypes 19F and 6A) showed that inhibition
of 19F may involve S. salivarius-mediated blocking of pneumococcal binding sites: a negative correlation was
observed between adherence of K12 and 19F, and no inhibition occurred when K12 was prevented from
contacting epithelial cells. K12-mediated inhibition of adherence by 6A may involve additional mechanisms, since
no correlation was observed between adherence of K12 and 6A, and K12 could inhibit 6A adherence in the
absence of cell contact.
Conclusions: These results suggest that S. salivarius employs several mechanisms, including blocking pneumococcal
binding sites, to reduce pneumococcal adherence to pharyngeal epithelial cells. These findings extend our
understanding of how probiotics may inhibit pneumococcal adherence and could assist with the development of
novel strategies to prevent pneumococcal colonisation in the future.
Keywords: Probiotics, Probiotic mechanisms, Respiratory tract, Streptococcus salivarius, Streptococcus pneumoniae,
Pneumococcus, Colonisation, Adherence
Background
Streptococcus pneumoniae (the pneumococcus) com-
monly colonises the nasopharynx of healthy humans, espe-
cially young children. Carriage is considered a prerequisite
for pneumococcal disease and facilitates the transmission
of pneumococci throughout communities [1]. Dissemin-
ation of pneumococci from the nasopharynx to other body
sites can give rise to diseases such as meningitis, sepsis,
pneumonia, and otitis media. An estimated 800,000 chil-
dren under the age of five die from pneumococcal infec-
tions each year, with most deaths occurring in low-income
countries where carriage rates are especially high [2]. Strat-
egies targeting the reduction of pneumococcal colonisation
could potentially reduce this burden of disease.
Current pneumococcal conjugate vaccines (PCVs) induce
protection against 10–13 of the most common disease-
causing serotypes via the induction of anti-capsular anti-
bodies. Although PCVs have successfully reduced carriage
and disease caused by vaccine serotypes, they are expensive
to produce and have led to an increase in colonisation by
non-vaccine serotypes (serotype replacement) [3]. In recent
years, there has been increased interest in the use of
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probiotics, which are defined as live microorganisms that
can confer a health benefit to the host, to reduce pathogen
colonisation and respiratory tract infections [4]. Proposed
mechanisms of probiotic action include inhibition of patho-
gen colonisation via competition for binding, direct inhib-
ition due to the activity of secreted antimicrobial molecules
and the induction of immunomodulatory effects in the
host [5–9].
Streptococcus salivarius is a member of the respiratory
tract microbiota and has been commercially available as
an oral probiotic for more than a decade [10]. Small
clinical trials have shown that administration of S. sali-
varius strains K12 and M18 can reduce the occurrence
of tonsillitis and otitis media [11] and reduce dental
plaque levels in children [12], as well as treat halitosis in
adults [13]. Several in vitro studies have found that S.
salivarius can prevent the growth of a range of respira-
tory pathogens, including the pneumococcus, through
production of megaplasmid-encoded bacteriocins and
bacteriocin-like inhibitory substances (BLIS) [7, 14–16].
However, the mechanisms by which they inhibit patho-
gen adherence in vivo are unknown. We have previously
shown that S. salivarius K12 can inhibit pneumococcal
adherence to a human epithelial cell line (CCL-23) [17].
Here, we demonstrate that the same phenomenon is ob-
served in Detroit 562 pharyngeal epithelial cells and inves-
tigate the inhibitory mechanisms involved, including the
role of the S. salivarius megaplasmid. Our results suggest
that S. salivarius K12 inhibits pneumococcal adherence by
blocking pneumococcal binding sites, although other
mechanisms such as direct interference through the action
of secreted molecules may also contribute.
Methods
Bacterial strains, cell lines and culture conditions
Bacterial isolates are described in Tables 1 and 2. Pneumo-
coccal isolates were selected to represent a range of
serotypes and based on their ability to adhere to human
epithelial cells. S. salivarius isolates were sourced from Blis
Technologies Ltd, New Zealand. All isolates were cultured
at 37 °C in 5 % CO2 on horse blood agar (HBA; Thermo
Fisher Scientific) plates, in Todd-Hewitt broth (THB;
Oxoid), or THB supplemented with 0.5 % (w/v) yeast ex-
tract (THY; Becton Dickinson). Deferred antagonism test-
ing was carried out on BaCa (Columbia agar base; Life
Technologies Ltd.) plates supplemented with human blood
(5 %, v/v) and CaCO3 (0.1 %, w/v) except where noted.
The Detroit 562 pharyngeal epithelial carcinoma cell
line (ATCC CCL-138) was maintained in RPMI 1640
(Sigma-Aldrich) supplemented with 10 % (v/v) foetal bo-
vine serum (FBS, Thermo Fisher Scientific). Monolayers
were released by incubation with 0.25 % trypsin/EDTA
(0.25 % (w/v) trypsin, 0.1 mM EDTA, Life Technologies)
for 10 min at 37 °C in 5 % CO2 and seeded into 24-well
trays at a concentration of 1.5 × 105 cells/well in RPMI
supplemented with 5 % FBS for use in adherence assays.
Deferred antagonism testing
Testing for deferred antagonism was performed as de-
scribed previously [18]. Briefly, overnight THB cultures
of S. salivarius (producer strain) were used to inoculate
a 1-cm-wide line down the middle of a human blood
agar plate (as described above). Plates were incubated
for 18 h at 37 °C in 5 % CO2, S. salivarius growth was
removed, and the plate inverted over a chloroform-
soaked cloth for 30 min to kill any remaining bacteria.
Residual chloroform was then evaporated by exposure of
the agar surface to air for 30 min. Overnight THB cultures
of pneumococcal indicator strains were then streaked at
Table 1 Streptococcus salivarius isolates used in this study
S. salivarius isolate Known bacteriocins
K12 SalA, SalB
K12 mp− –
M18 SalA, Sal9, SalM
M18 mp− –
A234 SalA
NR SalB
T18A SalA, SalB
T30A Unknown
Min5 SalA, SalB
20P3 SalA
SalA: salivaricin A [36]; SalB: salivaricin B [23]; Sal9: salivaricin 9 [37]; SalM:
salivaricin M [24]; mp: megaplasmid
Table 2 Pneumococcal isolates used in this study
Pneumococcal isolate Serotype Origin
PMP1081 1 Australia
PMP278 3 Fiji
PMP241 4 South Africa
PMP812 5 Bangladesh
PMP6 (ATCC® 6305™) 5 Germany
PMP1043 6A USA
PMP17 6A Fiji
PMP434 6B Fiji
PMP437 6C Fiji
PMP1086 7F Australia
PMP296 9V Fiji
PMP130 14 Fiji
PMP222 18C South Africa
PMP843 19F USA
PMP292 19A Fiji
PMP283 22F Unknown
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right angles to the previously grown S. salivarius and in-
cubated for a further 12–16 h. Plates were examined for
growth where S. salivarius had previously grown, and pre-
vention of pneumococcal growth recorded as + (observed)
or – (not observed).
Adherence assays
Adherence assays were performed as described previ-
ously [17] with several modifications. D562 cells seeded
into 24-well trays were washed twice with Hanks buff-
ered salt solution (HBSS; Gibco®, Life Technologies) be-
fore the addition of 500 μl/well RPMI without serum.
Bacteria were grown to log phase in THY (S. salivarius:
1.5 h, pneumococci: 3 h) and resuspended in 0.85 % (w/v)
NaCl (Merck) to ~1.5 × 109 CFU/ml. A 10-fold dilution
series of S. salivarius was prepared in 0.85 % NaCl and
10 μl aliquots of high (~1.5 × 107 CFU/well), medium
(~1.5 × 106 CFU/well), and low (~1.5 × 105 CFU/well) con-
centrations of bacteria were administered to duplicate wells
before centrifugation at 114 × g for 3 min to promote bac-
terial adherence to the cell monolayer. Plates were incu-
bated at 37 °C in 5 % CO2 for 1 h. Pneumococci were
prepared as above and added to all wells at a concentration
of ~1.5 × 106 CFU/well (MOI of 10 pneumococci: 1 D562
cell) 1 h after S. salivarius. Centrifugation was performed
as above and plates were incubated for a further 1 h. Cells
(and adherent bacteria) were then washed three times with
HBSS and harvested after the addition of 200 μl 0.25 %
trypsin/EDTA to each well, incubation for 10 min at 37 °C
in 5 % CO2, and addition of 800 μl of THY to each well
with mechanical disruption. Lysates were stored at −20 °C
until tested. Pneumococcal adherence (genome copies/
well) was determined by quantitative real-time PCR
(qPCR) targeting lytA (see below). The effect of bacterial
infection on D562 cells was monitored microscopically and
no significant cytopathic effects were observed during the
adherence assay conditions. The effect of S. salivarius on
pneumococcal adherence was calculated by normalising all
treatments against wells containing pneumococci alone.
The ability of the pneumococcal isolates to invade cells
was measured by incubating cells with media containing
10 μg/ml penicillin and 200 μg/ml gentamicin for 15 min
after incubation with pneumococci for 1 h (Additional file
1), confirming the validity of this model to investigate ad-
herence. The adherence of S. salivarius to D562 cells at the
time of pneumococcal administration was calculated fol-
lowing incubation of ~1.5 × 106 CFU/well bacteria for 1 h
at 37 °C in 5 % CO2. Cells were washed three times with
HBSS to remove non-adherent bacteria and harvested as
above. CFU/well was determined by viable count on HBA
plates and expressed as mean % adherence ± standard devi-
ation compared to the inoculum added.
We performed preliminary experiments to determine
whether heparin, which can inhibit pneumococcal
adherence to epithelial cells in vitro by competitively bind-
ing to glycosylaminoglycans [19], could also inhibit S. sali-
varius adherence to D562 cells. Cells were incubated with
100 U/well of heparin (Pfizer) for 1 h before the addition
of S. salivarius as above and results expressed as % adher-
ence compared to S. salivarius without heparin. S. salivar-
ius adherence to D562 cells over time was measured by
qPCR targeting dex (see below).
We also investigated whether non-adherent S. salivarius
had an effect on pneumococcal adherence. To do this, ad-
herence assays were performed as described above, except
that wells were washed three times with HBSS to remove
unbound S. salivarius and fresh medium was added after
S. salivarius pre-administration and before the addition of
pneumococci. To determine the inhibitory effect of S. sali-
varius in the absence of cell contact, S. salivarius was pre-
administered to D562 cells via permeable transwell inserts
with a pore size of 0.4 μm (Corning, In vitro Technolo-
gies). To further investigate the mechanisms involved in
the inhibition of pneumococcal adherence, preparations of
K12 were: a) heat-killed by incubating at 70 °C for 30 min
with their lack of viability confirmed by the absence of
growth on HBA; b) enzymatically treated to remove outer
surface proteins and carbohydrates of S. salivarius K12 by
(i) resuspending K12 inocula in a final concentration of
5 mg/ml pronase E [20], or (ii) by the addition of 5 μl of
1 mg/ml sodium periodate [21] to K12 inocula prepared
in 0.85 % NaCl for 15 min at 37 °C in 5 % CO2, and c) re-
ducing K12 protein synthesis by resuspending K12 inocula
in 2 mg/ml spectinomycin and incubating for 30 min at
37 °C in 5 % CO2. Following all treatments, K12 inocula
were washed twice in 0.85 % NaCl prior to use in adher-
ence assays.
qPCR
DNA extraction and pneumococcal qPCR assays were
performed as described previously [17]. Primers (Sigma
Aldrich) and dual-labelled probes (Eurogentec) were de-
signed to detect chromosomal (dextranase gene, dex)
and megaplasmid (mp) target sequences in S. salivarius.
Primer/probe sequences and final concentrations were as
follows: dexF2: TGAAGCAGATAACTTGGTGGTG (300
nM); dexR2: CTCTCTGCTGGCACAGCTT (300 nM);
dex probe2: HEX-AGAAGTAGGTCCATCATCTGCC-3′-
BHQ-1 (75 nM); mpF: AAGCCTTGTGCATCGACTCT
(200nM); mpR: AACCAAGACGCGACTGTTGA (200
nM); mp probe: FAM-TGACCCTTTTTGTTGGTCGT-
3′-BHQ-1 (300 nM). Specificity of both assays was con-
firmed by sequencing the amplified product and testing
against a panel of closely related streptococcal species
(Additional file 2: Table S1). qPCR reactions were carried
out in duplicate using Agilent Brilliant III master mix (Agi-
lent Technologies, Integrated Sciences), containing 1 μl of
template DNA in 25 μl final volume using a Stratagene
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Mx3005P qPCR machine (Agilent Technologies). The cyc-
ling conditions were: 1 × 3 min at 95 °C, 40 × 20 s at 95 °C
followed by 20 s at 60 °C. Pneumococcal and S. salivarius
DNA was quantified using standard curves of reference
strain isolates (ATCC 6305 and K12, respectively) and bac-
terial loads were calculated as described previously [22],
based on 1 pg of genomic DNA being equivalent to 447.4
pneumococcal cells and 422.1 S. salivarius cells (assuming
one genome per cell, and one copy of the target gene per
genome).
Statistical analysis
Data were analysed using Prism 6.0d (GraphPad Soft-
ware, Inc.) and Excel (Microsoft). Student’s t-test was
used to compare pneumococcal adherence in all treat-
ment groups. Spearman’s rank test was used to correlate
pneumococcal and S. salivarius K12 adherence in adher-
ence assays. A p value of < 0.05 was considered statisti-
cally significant for all assays. For all experiments n ≥ 3
unless otherwise stated.
Results
S. salivarius reduces pneumococcal adherence to
pharyngeal epithelial cells
Previous studies in our laboratory demonstrated that S.
salivarius K12 inhibits pneumococcal adherence to
CCL-23 human epithelial cells in vitro, with the stron-
gest effect seen when K12 was added before pneumo-
cocci (pre-administration). In this study, we investigated
the mechanisms underlying this inhibition using a cell
line more relevant to the pneumococcal ecological niche
of the nasopharynx, Detroit 562 human pharyngeal
epithelial cells (D562), and two isolates representing se-
rotypes that commonly colonise (6A [PMP1043] and
19F [PMP843]). Pneumococcal adherence was mea-
sured following pre-administration of commercial pro-
biotic S. salivarius strains K12 or M18 at high, medium
and low doses.
All doses of K12 significantly inhibited 6A and 19F adher-
ence (p < 0.001, Fig. 1). All doses of M18 inhibited 6A ad-
herence (high: p < 0.001, medium: p < 0.001, low: p = 0.023,
Fig. 1a), but only the high dose inhibited 19F adher-
ence (p < 0.001, Fig. 1b). K12 adherence to D562 cells
was higher than that of M18 (532.3 ± 86.49 % vs. 12.5 ±
8.14 %, p < 0.001). Heparin, which is known to inhibit
pneumococcal adherence to epithelial cells by competing
for binding to cell surface glycosylaminoglycans [19], did
not affect S. salivarius K12 adherence to D562 cells
(115.8 ± 27.81 %, p = 0.380, Student's t-test).
K12 adherence showed significant negative correl-
ation with 19F adherence but not with 6A adherence
(19F: r = −0.68, p = 0.002; 6A: r = −0.12, p = 0.66; Fig. 2).
Significant inhibition of pneumococcal adherence was
also observed following removal of non-adherent K12 by
washing prior to the addition of pneumococci (Direct +
wash, Table 3: all doses p < 0.001).
The K12 megaplasmid is essential to prevent
pneumococcal growth but not adherence
The megaplasmids of S. salivarius K12 and M18 encode
bacteriocins that prevent the growth of a range of bacterial
species on solid media [14, 16, 23, 24], but their roles in in-
hibition of pneumococcal growth or adherence are un-
known. We compared the ability of K12, M18, their
megaplasmid-negative derivatives, and a panel of S. salivar-
ius strains to inhibit the growth of 15 pneumococcal isolates
by deferred antagonism. S. salivarius strains K12, M18,
A234, NR, T18A and Min5 inhibited all of the pneumococ-
cal isolates tested (Table 4). Neither megaplasmid-negative
strain (K12mp− or M18mp−) or strain T30A prevented the
growth of any of the pneumococcal isolates tested (Table 4).
Since the S. salivarius megaplasmids were essential to
prevent the growth of pneumococci, and K12 caused a
greater reduction in pneumococcal adherence than M18
(Fig. 1), we next compared the ability of K12 and K12 mp−
strains to inhibit pneumococcal adherence to D562 cells.
Although the exact copy number of the megaplasmid is
Fig. 1 Pneumococcal adherence of serotypes 6A (a) and 19F (b) to pharyngeal epithelial cells following pre-administration of S. salivarius. Approximately
1.4 × 106 CFU pneumococci were added to D562 monolayers at an MOI of 11:1. Pneumococcal adherence was determined when incubated with
pneumococci alone (Pnc, normalised to 100 %), or pre-incubated for 1 h with S. salivarius K12 or M18 at high (~1.6 × 107 CFU), medium (~1.6 × 106 CFU),
or low (~1.6 × 105 CFU) doses. Data are mean + SD; n≥ 3. * indicates p< 0.05, ** indicates p< 0.001 when compared to Pnc alone (Student’s t-test)
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unknown, preliminary qPCR analysis confirmed that the
ratio of K12 chromosomal DNA to megaplasmid DNA
remained stable during bacterial growth (1.43, n = 1) and
throughout assay conditions (1.17 and 1.20 after 1 and 2 h
incubation with D562 monolayer, respectively, n = 1). All
doses of K12 mp− significantly inhibited 6A adherence
(high: p < 0.001, medium: p < 0.001, low: p = 0.016, Fig. 3a).
When compared to K12, there was some evidence that
the K12 mp− strain resulted in less inhibition than the K12
strain, but this difference was only statistically significant
at the high dose (p = 0.044, Fig. 3a). For the 19F strain,
only the high and medium doses of K12 mp− significantly
inhibited pneumococcal adherence. We found no differ-
ences in the ability of K12 and K12 mp− to adhere to D562
cells (532 ± 86.49 % vs. 511 ± 6.92 %, p = 0.695) or in their
adherence to D562 cells over time (Fig. 4, p > 0.05 for all
time points).
Cell contact is required for K12 to inhibit adherence by
serotype 19F, but not serotype 6A
To determine whether contact of S. salivarius with D562
cells was required to inhibit pneumococcal adherence,
we performed adherence assays in which K12 was
administered using transwell inserts, preventing direct
contact with epithelial cells but allowing the passage of se-
creted molecules. Using this transwell system, no inhib-
ition of 19F adherence was observed at any dose, while 6A
adherence was inhibited at the medium (p = 0.049) and
low (p < 0.001) doses (Table 3). Preliminary experiments
showed that culture supernatants did not inhibit pneumo-
coccal growth in the deferred antagonism test.
Protein synthesis may be required for K12 to inhibit 6A
adherence
The above experiments indicated the involvement of mul-
tiple mechanisms for S. salivarius inhibiting pneumococcal
adherence. We further investigated the molecular mecha-
nism(s) of S. salivarius K12 inhibition of 6A adherence by
performing different treatments on the K12 inoculum prior
to its use in adherence assays. Denaturing proteins and kill-
ing K12 cells (heat-treatment), interrupting protein synthe-
sis (spectinomycin treatment), and removing outer surface
carbohydrates (sodium periodate treatment) and proteins
(pronase E treatment) all reduced inhibition of 6A adher-
ence compared with untreated K12 (Fig. 5). However, only
Fig. 2 Correlation of adherence of S. salivarius K12 and pneumococcal serotype 6A (a) and 19F (b) adherence to pharyngeal epithelial cells.
Adherence of S. salivarius and pneumococci to D562 monolayers was determined following pre-incubation for 1 h with high (~1.6 × 107 CFU),
medium (~1.6 × 106 CFU), or low (~1.6 × 105 CFU) doses of S. salivarius K12 and subsequent incubation with ~1.4 × 106 CFU pneumococci for
1 h. r = Spearman rank correlation coefficient
Table 3 Pneumococcal adherence to pharyngeal epithelial cells following pre-administration of S. salivarius K12 by various methods
Pneumococcal adherencea
Direct Transwell Direct + wash
Pneumococcal serotype K12 Dosec % (95 % CI) p valueb % (95 % CI) p valueb % (95 % CI) p valueb
6A High 16.6 (6.8, 26.5) <0.001 90.5 (23.9, 157.1) 0.698 25 (12.5, 37.4) <0.001
Medium 19.6 (14.7, 24.4) <0.001 61.5 (18.4, 104.5) 0.049 45.2 (21.9, 68.5) <0.001
Low 35.4 (12.3, 58.5) <0.001 44.1 (22.8, 65.5) <0.001 45.1 (29.1, 61.1) <0.001
19F High 10.4 (2.5, 18.4) <0.001 84.7 (33.6, 135.7) 0.338 41.8 (17.6, 66.4) <0.001
Medium 21.8 (1.7, 41.8) <0.001 121.3 (16.5, 226.2) 0.581 31.4 (13.2, 49.6) <0.001
Low 50.7 (33.8, 67.5) <0.001 102.2 (33.7, 170.5) 0.933 45.3 (16.7, 74.0) <0.001
aDirect: pre-administration of K12 directly onto D562 monolayer; Transwells: pre-administration of K12 via transwell inserts; Direct + wash: pre-administration of
K12 directly onto D562 monolayers followed by a washing step to remove non-adherent K12
bp values calculated from pneumococcal adherence alone compared to pneumococcal adherence following different methods of K12 pre-administration (Student’s
t test, *p < 0.05)
cHigh: ~1.5 × 107 CFU/ml; Medium: ~1.5 × 106 CFU/ml and Low: ~1.5 × 105 CFU/ml
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spectinomycin-treated K12 could no longer significantly in-
hibit 6A adherence (p = 0.402, Fig. 5).
Discussion
In this study, we found that various bacteriocin-producing
strains of S. salivarius can prevent pneumococcal growth
on solid media and that the commercial probiotic strains,
K12 and M18, inhibit pneumococcal 6A and 19F adherence
to a pharyngeal epithelial cell line. Studies investigating the
probiotic mechanisms of S. salivarius have largely focused
on the role of bacteriocins and BLIS. The ~190 kb mega-
plasmid of S. salivarius K12 harbours genes encoding
the bacteriocins salivaricin A2 and B, which prevent the
growth of some bacterial pathogens, including Streptococcus
pyogenes, in vitro [7, 14, 15]. Our results showed that the
K12 megaplasmid is required to prevent pneumococcal
growth in vitro, but is not essential to inhibit pneumococcal
adherence. Therefore the primary mechanism of inhibition
of pneumococcal adherence in this model does not appear
to be mediated by megaplasmid-encoded bacteriocins; al-
though we note that lack of inhibition of 19F adherence by
a low dose of K12mp- indicates a possible role for the mega-
plasmid at this concentration. Instead, our findings indi-
cated that S. salivarius K12 can inhibit pneumococcal
adherence by blocking pneumococcal binding sites on
D562 cells. We observed a correlation between S. salivarius
K12 adherence to D562 cells and inhibition of adherence
by pneumococcal isolate PMP843 (19F). We also found that
Table 4 Deferred antagonism of S. salivarius strains against a panel of pneumococcal isolates
S. salivarius producer strain
Pneumococcal test strain Serotype K12 K12 mp− M18 M18 mp− A234 NR T18A T30A Min5 20P3
PMP1081 1 + − + − + + + − + +
PMP278 3 + − + − + + + − + +
PMP241 4 + − + − + + + − + −
PMP812 5 + − + − + + + − + +
PMP1043 6A + − + − + + + − + −
PMP17 6A + − + − + + + − + +
PMP434 6B + − + − + + + − + +
PMP437 6C + − + − + + + − + +
PMP1086 7F + − + − + + + − + +
PMP296 9V + − + − + + + − + +
PMP130 14 + − + − + + + − + −
PMP222 18C + − + − + + + − + +
PMP292 19A + − + − + + + − + −
PMP843a 19F + − + – NT NT NT NT NT NT
PMP283 22F + − + − + + + − + +
“+” indicates inhibition of pneumococcal growth and “−" indicates no inhibition, n = 2
NT not tested
aperformed on horse blood agar plates
Fig. 3 Adherence of pneumococcal serotypes 6A (a) and 19F (b) to pharyngeal epithelial cells following pre-administration of megaplasmid positive
(K12) and negative (K12 mp−) S. salivarius K12 strains. Approximately 1.5 × 106 CFU pneumococci were added to D562 monolayers at an MOI of 10:1.
Pneumococcal adherence was determined when incubated with pneumococci alone (Pnc, normalised to 100 %), or pre-incubated for 1 h
with S. salivarius K12 or S. salivarius K12mp- at high (~2 × 107 CFU); medium (~2 × 106 CFU, med); or low (~2 × 105 CFU) doses. Data are mean + SD; n≥
6. * indicates p < 0.05, ** indicates p < 0.001 when compared to Pnc alone (Student’s t test)
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K12 contact with cells was essential for this inhibition. K12
binding to D562 cells did not require megaplasmid-
encoded molecules, since a megaplasmid-negative strain of
K12 displayed equal adherence. We observed differences in
the inhibition of pneumococcal adherence depending on
both the strain of S. salivarius used and the pneumococcal
isolate tested. This was not unexpected, given that S. sali-
varius strains vary in their capacity to adhere to epithelial
cells and inhibit other pathogens [7, 15, 16]. The pneumo-
coccus is a diverse pathogen, with different strains and
serotypes known to behave differently in vitro and in vivo
[25, 26]. Overall, S. salivarius K12 displayed stronger inhib-
ition of pneumococcal adherence than the M18 strain, pos-
sibly due to its increased capacity to adhere to D562 cells.
Interestingly, K12 adherence to D562 cells did not correlate
with 6A adherence, suggesting that mechanisms other than
S. salivarius-mediated blocking of pneumococcal binding
sites on epithelial cells may be involved in the inhibition of
6A adherence. This was further supported by the inhibition
of 6A adherence by all doses of M18 despite its low adher-
ence capability. Although a high dose of megaplasmid-
negative K12 could still inhibit 6A adherence, the effect was
significantly less than that observed with megaplasmid-
positive K12, indicating a possible contribution to inhibition
by the K12 megaplasmid in this assay. Transwell experi-
ments demonstrated that for 19F, contact of S. salivarius
K12 with D562 cells was required to inhibit pneumococcal
adherence, consistent with a previous report showing that
contact with epithelial cells was needed for S. salivarius
K12 to inhibit adherence by S. pyogenes to HEp-2 cells [27].
However, low doses of K12 administered in the absence of
cell contact could inhibit adherence of 6A. This could be
due to bacteriocins or other secreted products, which may
not necessarily be encoded on the megaplasmid. The differ-
ences observed using varying doses of probiotic suggest that
quorum sensing may play a role in the expression of S. sali-
varius genes relevant to pneumococcal inhibition.
Further transwell experiments that test the K12
megaplasmid-negative strain may determine whether
the molecules involved are chromosomally or plasmid
encoded. Preliminary attempts to detect if bacteriocins
were secreted through transwell membranes by de-
ferred antagonism were unsuccessful, however this ap-
proach may have been insufficiently sensitive.
Overall, the data obtained in this study suggest that the
primary mechanism by which S. salivarius K12 inhibits
pneumococcal adherence to D562 cells is by blocking
pneumococcal attachment to the epithelial cell surface. A
number of pneumococcal surface molecules have been
shown to play a role in adherence, such as the adhesion
molecule PsaA, which binds to cell surface carbohydrates
[28]. For S. salivarius, various cell surface molecules includ-
ing fibrils and fimbriae have been implicated in adherence
[29]. As heparin does not block S. salivarius adherence to
D562 cells, glycosylaminoglycans do not seem to be a
shared cell surface receptor. Since airway epithelial cells de-
rived from carcinomas, such as D562 cells, can display al-
tered expression of surface molecules compared to primary
human epithelial cells [30], further investigation of com-
mon receptors used by these species should include testing
of primary cells. Although inhibition of pneumococcal ad-
herence could be due to competition for receptor-mediated
binding, it could also result through a less specific
mechanism, such as steric hindrance, or the ability of
S. salivarius to mask pneumococcal binding sites.
Other potential mechanisms by which S. salivarius may
inhibit pneumococcal adherence, such as immune modu-
lation of epithelial cells [31], were not examined in this
study. Additionally, the in vitro model lacks the complex-
ity of the nasopharynx, which can harbour a wide range of
colonising bacterial species that interact with each other
and with epithelial cells.
Fig. 4 Time course of S. salivarius adherence to D562 cells. Cells were
inoculated with either ~1.1 × 105 CFU of S. salivarius K12 or ~1.9 ×
105 CFU of S. salivarius K12mp- and the number of adherent bacteria
measured over three hours. Median ± IQR for both S. salivarius isolates
are depicted (n≥ 2)
Fig. 5 Adherence of pneumococcal serotype 6A to pharyngeal epithelial
cells following pre-administration of treated S. salivarius K12. Approximately
1.5 × 106 CFU pneumococci were added to D562 monolayers at an MOI
of 10:1. Pneumococcal adherence was determined when incubated
with pneumococci alone (Pnc, normalised to 100 %), or pre-incubated
for 1 h with approximately 1.5 × 107 CFU S. salivarius K12 (untreated), or
treated with sodium periodate, Pronase E, heat-killed (heat), or
spectinomycin. Data are mean+ SD; n≥ 3. * indicates p< 0.05, ** indicates
p< 0.001 when compared to Pnc alone (Student’s t test)
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Whilst megaplasmid-encoded bacteriocins are re-
quired to inhibit the growth of pneumococci on solid
media, our data suggest that it is the adherence of S. sal-
ivarius to epithelial cells that primarily blocks pneumo-
coccal adherence in vitro. Therefore, strategies to use S.
salivarius as a probiotic in the respiratory tract should
optimise the ability of this species to colonise the target
tissue. In vitro studies performed in our laboratory, and
by others, have shown that the addition of probiotic bac-
teria to epithelial cells prior to pathogen administration
is more effective than attempting to disrupt established
pathogen colonisation [17, 27]. In clinical studies, high
doses of M18 achieve greater colonisation rates and
density in the oral cavity compared to lower doses [15].
Clinical studies of S. salivarius K12 as an oral probiotic
have involved daily administration of high doses of the
bacterium in an effort to achieve long-term colonisation
of the oral cavity [32–34]. S. salivarius may be better
suited as a probiotic for the oral cavity, where it predomi-
nates, than for the nasopharynx, the preferred niche of the
pneumococcus. Strategies that facilitate S. salivarius ad-
herence to the nasopharyngeal epithelium, such as the
nasal spray recently employed by Santagati and colleagues
[35], would likely be needed for this probiotic to inhibit
pneumococcal colonisation in vivo.
Conclusions
Bacteriocin-encoding megaplasmids of S. salivarius strains
K12 and M18 were essential to prevent pneumococcal
growth on solid media but were not required to inhibit
pneumococcal adherence to pharyngeal epithelial cells.
Our results suggest that S. salivarius K12 employs several
mechanisms, including blocking pneumococcal binding
sites, to reduce pneumococcal adherence to pharyngeal
epithelial cells. Further research is needed to identify the
specific molecules involved. These findings contribute to
our understanding of how probiotics may inhibit pneumo-
coccal adherence and could assist with the development of
novel strategies to prevent pneumococcal colonisation in
the future.
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